RBI Granted 'Fast Track' Designation by FDA, Validating Its Direc

Regeneration Biomedical received FDA Fast Track designation for its direct-to-brain autologous stem cell therapy for Alzheimer's disease, following Phase I results showing safety and improvements in CSF biomarkers. The company is now cleared to begin a multi-centre Phase II placebo-controlled trial with repeated dosing.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.